Yes, I agree with that. There's a middle ground and I would be open to see some improvements there. It would be welcomed.
I said my comment in response to other (less levelheaded) posters. I have seen so many ASX biotech and health companies spend so much time in attention in the IR and PR cycle, but they end up never moving away from the constant capital raising cycle. Any value created from raising awareness of a company's prospects are lost as soon as a capital raise is needed for working capital. NEU obviously doesn't have this problem, but people seem to forget this is incredibly rare on the ASX, outside of the big players.
Ann: DAYBUE net sales US$87.1 million in Q4 2023, page-59
-
- There are more pages in this discussion • 21 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.05 |
Change
-0.510(3.50%) |
Mkt cap ! $1.795B | |||
| Open | High | Low | Value | Volume |
| $14.38 | $14.42 | $13.94 | $6.419M | 454.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $13.99 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.07 | 6644 | 4 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |